Year
2009
Status
Exited
Team
Field
Antibody technology platform
Location
Rotterdam (The Netherlands), Gent (Belgium)
Fund
BGV I
arGEN-X
arGEN-X employs a superior therapeutic antibody platform for the generation of human monoclonal antibodies. arGen-X
successfully completed an IPO in 2014 at EuroNext Brussels.